This study is in progress, not accepting new patients
A Study to Test the Safety and Efficacy of the Drug Larotrectinib for the Treatment of Tumors With NTRK-fusion in Children
Summary
- Eligibility
- for people ages up to 21 years (full criteria)
- Location
- at Los Angeles, California and other locations
- Dates
- study startedestimated completion
- Principal Investigator
- by Arun Singh
Description
Summary
Official Title
Keywords
Eligibility
Locations
Lead Scientist at UCLA
- Arun Singh
HS Associate Clinical Professor, Medicine. Authored (or co-authored) 67 research publications
Details
- Status
- in progress, not accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Bayer
- ID
- NCT02637687
- Phase
- Phase 1/2 research study
- Study Type
- Interventional
- Participants
- Expecting 155 study participants
- Last Updated